Asad Haider
Stock Analyst at Goldman Sachs
(4.71)
# 690
Out of 5,070 analysts
139
Total ratings
81.7%
Success rate
24.1%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYO: 4519 Chugai Pharmaceutical Co., Ltd. | Reiterated: Buy | ¥8,750 | ¥6,503 | +34.55% | 1 | Oct 20, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,371 → $1,413 | $1,283.66 | +10.08% | 26 | Oct 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Rated: Hold | $63 | $61.68 | +2.14% | 13 | Oct 19, 2026 | |
| MRK Merck & Co. | Rated: Buy | $160 → $155 | $148.30 | +4.52% | 23 | Oct 16, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $127 | $91.17 | +39.30% | 8 | Oct 13, 2026 | |
| PCVX Vaxcyte | Reiterated: Hold | $67 → $85 | $66.23 | +28.34% | 3 | Oct 6, 2026 | |
| JNJ Johnson & Johnson | Reiterated: Buy | $282 | $259.36 | +8.73% | 24 | Aug 25, 2026 | |
| RPRX Royalty Pharma | Reiterated: Buy | $59 → $66 | $62.25 | +6.02% | 4 | Aug 6, 2026 | |
| PFE Pfizer | Reiterated: Hold | $26 | $30.11 | -13.65% | 20 | Aug 4, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $244 | $289.08 | -15.59% | 8 | Jul 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $37 → $38 | $21.50 | +76.74% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $17 → $18 | $21.28 | -15.41% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $438.94 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $8.87 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $168 | $174.19 | n/a | 1 | Dec 14, 2018 |
Chugai Pharmaceutical Co., Ltd.
Oct 20, 2026
Reiterated: Buy
Price Target: ¥8,750
Current: ¥6,503
Upside: +34.55%
Eli Lilly and Company
Oct 20, 2026
Reiterated: Buy
Price Target: $1,371 → $1,413
Current: $1,283.66
Upside: +10.08%
Bristol-Myers Squibb Company
Oct 19, 2026
Rated: Hold
Price Target: $63
Current: $61.68
Upside: +2.14%
Merck & Co.
Oct 16, 2026
Rated: Buy
Price Target: $160 → $155
Current: $148.30
Upside: +4.52%
BioNTech SE
Oct 13, 2026
Reiterated: Buy
Price Target: $127
Current: $91.17
Upside: +39.30%
Vaxcyte
Oct 6, 2026
Reiterated: Hold
Price Target: $67 → $85
Current: $66.23
Upside: +28.34%
Johnson & Johnson
Aug 25, 2026
Reiterated: Buy
Price Target: $282
Current: $259.36
Upside: +8.73%
Royalty Pharma
Aug 6, 2026
Reiterated: Buy
Price Target: $59 → $66
Current: $62.25
Upside: +6.02%
Pfizer
Aug 4, 2026
Reiterated: Hold
Price Target: $26
Current: $30.11
Upside: -13.65%
AbbVie
Jul 21, 2026
Reiterated: Hold
Price Target: $244
Current: $289.08
Upside: -15.59%
May 7, 2026
Reiterated: Hold
Price Target: $37 → $38
Current: $21.50
Upside: +76.74%
May 6, 2026
Reiterated: Sell
Price Target: $17 → $18
Current: $21.28
Upside: -15.41%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $438.94
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $8.87
Upside: n/a
Dec 14, 2018
Reiterated: Buy
Price Target: $168
Current: $174.19
Upside: n/a